Advanced Filters
noise
Found 842 clinical trials
M Marc W Haut, PhD

Low-Intensity Focused Ultrasound (LIFU) Neuromodulation

This study is a prospective, single-center, single-arm early feasibility study, to establish safety and tolerability of LIFU for neuromodulation in patients with mild cognitive impairment ( MCI) due to Alzheimer's disease.

45 - 85 years of age All Phase N/A
M Maibritt Horning, MSc

Study on the Effect of 40 Hz Non-Invasive Light Therapy System

The ALZLIGHT STAGE III Study is a continuation of the ALZLIGHT Pilot - Study on Safety, Feasibility and Neural Activation of Non-Invasive Light Therapy System. As with the first two stages, this study will examine whether entrainment of 40 Hz neural oscillation by novel 40 Hz Invisible Spectral Flicker is …

55 years of age All Phase N/A
D Debbie Chung, PhD

Combating Alzheimer's Through Sleep and Exercise

The purpose of this research is to see how sleep and exercise affects dementia risk over time.

45 - 80 years of age All Phase N/A
C Che-Sheng Chu, MD

40Hz tACS in Treating Cognitive Function and Modulating Neurophysiology of Patients With Alzheimer's Disease

Gamma brain activity is crucial for cognitive function and intra-brain communication. Gamma frequency stimulation via transcranial alternating current stimulation(tACS) might alleviate memory deficits on both animal models of Alzheimer's disease (AD) and clinical trial. The study aims to assess the safety and efficacy of tACS on cognitive function and modulating …

60 - 90 years of age All Phase N/A
K Kathy Richards, PhD

Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease

Nighttime agitation in persons with Alzheimer's disease causes patient suffering, distresses caregivers, and often results in prescriptions for harmful antipsychotics. Effective treatments are lacking because of limited knowledge of the etiology of nighttime agitation. The investigators propose a clinical trial to better elucidate whether a sleep disorder, restless legs syndrome, …

55 years of age All Phase 4
M Merav Shor

A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease.

20 subjects with mild to moderate AD will be enrolled in the study and randomized at a 1:1 ratio to receive the study drug or placebo tablets, respectively. All subjects will be administered the drug/placebo twice daily (BID), two tablets each time, for 52 weeks. Subjects will be allowed to …

55 - 85 years of age All Phase 2

The Use of Memantine for Prevention of Alzheimer's Disease

As the US population ages, the prevalence of dementia is increasing, and Alzheimer's Disease (AD) is the most prevalent one. Solving the Alzheimer's Disease (AD) epidemic is likely to require preventive therapy beginning many years before symptoms are expected to be evident in at-risk individuals. AD is caused by the …

50 - 65 years of age All Phase 2

[18F]PI-2620 Phase 3 Histopathological Study

This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with [18F]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and controls during lifetime when compared to histopathology obtained after death and completion of brain autopsy.

50 years of age All Phase 3
X Xiaodong Pan

Effect of Astragalus Membranaceus on the Improvement of Cognitive Function in Alzheimer's Disease

Alzheimer's disease (AD), the most common cause of dementia, is characterized by cognitive impairment, mental and behavioural abnormalities, and social dysfunction. Current treatments can only delay the progression of AD, not cure it completely. In vitro studies have shown that Astragalus has toxic effects such as anti-hypoxia injury of nerve …

30 - 80 years of age All Phase 2

Perturbation Training Reduces Falls in People With AD

This study will examine the overall capacity of people with Alzheimer's disease learning fall-resistant skills from perturbation training.

65 - 90 years of age All Phase N/A

Simplify language using AI